Effects of HDAC Depletion and Inhibition in HeLa Cells
Author Information
Author(s): Marielle Dejligbjerg, Morten Grauslund, Thomas Litman, Laura Collins, Xiaozhong Qian, Michael Jeffers, Henri Lichenstein, Peter Buhl Jensen, Maxwell Sehested
Primary Institution: National University Hospital, Copenhagen, Denmark
Hypothesis
How do class I histone deacetylase (HDAC) depletion and inhibition affect gene expression and cell viability in HeLa cells?
Conclusion
Depletion of HDAC1 increases resistance to the HDAC inhibitor belinostat, indicating its potential as a predictive biomarker.
Supporting Evidence
- HDAC knockdown reduced cell viability by 20-35%.
- Belinostat treatment increased apoptosis significantly.
- Only 1.6-3.4% of altered genes overlapped between HDAC knockdown and HDACi treatment.
Takeaway
When scientists blocked certain proteins in cancer cells, they found that one of these proteins made the cells less sensitive to a cancer drug.
Methodology
The study used siRNA technology to knock down HDAC1, 2, and 3 in HeLa cells and compared the effects with treatment using belinostat and valproic acid.
Limitations
The study primarily focused on HeLa cells, which may not represent all cancer types.
Participant Demographics
HeLa cells, a human cervical cancer cell line.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website